Page 19 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

General introduction
2018. 1
34. Vreken P, VanKuilenburg ABP, Meinsma R, et al. A point mutation in an invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase
deficiency. J Inherit Metab Dis. 1996;19(5):645-654.
35. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other
fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-
analysis. J Clin Oncol. 2014;32(10):1031-1039.
36. Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and
haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin
Cancer Res. 2011;17(10):3455-3468.
37. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G,
c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(16):1639- 1650.
38. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5(11):2895-2904.
39. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26(13):2131-2138.
40. Van Kuilenburg ABP, Meijer J, Mul ANPM, et al. Intragenic deletions and a deep intronic mutation affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms causing 5-fluorouracil toxicity. Hum Genet. 2010;128(5):529-538.
41. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10(6):931-944.
42. Deenen MJ, Meulendijks D, Cats A, et al. Upfront Genotyping of DPYD*2A to Individualize
Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-234.
43. Lunenburg CATC, Henricks LM, Guchelaar HJ, et al. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016;54:40-
48.
44. Henricks LM, Lunenburg CATC, Meulendijks D, et al. Translating DPYD genotype into DPD
phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16(11):1277-1286.
45. Henricks LM, Lunenburg CATC, de Man FM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol.
2018;19(11):1459-1467.
46. Henricks LM, Lunenburg CATC, de Man FM, et al. A cost analysis of upfront DPYD genotype-guided
dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2018;107:60-
67.
47. Lunenburg CATC, Henricks LM, Dreussi E, et al. Standard fluoropyrimidine dosages in
chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele
carriers. Eur J Cancer. 2018;104:210-218.
48. Lunenburg CATC, van Staveren MC, Gelderblom H, Guchelaar HJ, Swen JJ. Evaluation of clinical
implementation of prospective DPYD genotyping in 5-fluorouracil- or capecitabine-treated 17